TriangleNCT01408043 · OUTCOME
Collection Using Plerixafor, Etoposide, and Filgrastim
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Within 2 days of apheresis
What was measured
Number of participants able to collect equal to or more than 8 x 10\^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10\^6 CD34+ cells/kg are defined as normal mobilizers.
Analysis population: All participants that went on study
Groups in this outcome
Treatment (Stem Cell Supermobilization)
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
| Group | Source count |
|---|---|
| Treatment (Stem Cell Supermobilization) | 25 |
Reported measurements
Supermobilizers
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Stem Cell Supermobilization) | 7 | Not reported | Not reported | Not reported | Not reported |
Normal Mobilizers
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Stem Cell Supermobilization) | 17 | Not reported | Not reported | Not reported | Not reported |
Non mobilizers
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (Stem Cell Supermobilization) | 1 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 7
- title
- Supermobilizers
- categories
- measurements
- group Id
- OG000
- value
- 17
- title
- Normal Mobilizers
- categories
- measurements
- group Id
- OG000
- value
- 1
- title
- Non mobilizers
- denoms
- counts
- group Id
- OG000
- value
- 25
- units
- Participants
- description
- Number of participants able to collect equal to or more than 8 x 10\^6 CD34+ cells/kg with addition of plerixafor to etoposide and filgrastim. These participants are defined as supermobilizers. Participants with less than 8 x 10\^6 CD34+ cells/kg are defined as normal mobilizers.
- groups
- description
- Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
- id
- OG000
- title
- Treatment (Stem Cell Supermobilization)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- All participants that went on study
- reporting Status
- POSTED
- time Frame
- Within 2 days of apheresis
- title
- Collection Using Plerixafor, Etoposide, and Filgrastim
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice